July 2010 - Volume 35 - Issue 7
pp: 8-56

Editor's Memo

Guide to Care for patients

Pain Solutions

Advocacy In Practice

Literature Review

This Just In

Medication Update


Overcoming barriers to new treatment options for hepatitis C

Brennan, Christine S.

The Nurse Practitioner. 35(7):20-29, July 2010.

There have been significant advancements made in the treatment of hepatitis C virus (HCV) infection, however, not all who could benefit have received access. This article reviews current guidelines for HCV treatment and proposes strategies to overcome potential barriers to state-of-the-art therapy.


Treating antiretroviral-induced dyslipidemia in HIV-infected adults

Scordo, Kristine A.

The Nurse Practitioner. 35(7):32-37, July 2010.

Although limited information about the success of lipid-lowering therapy in HIV-infected patients is available from controlled studies, current guidelines support managing dyslipidemia in these patients similar to the general population per the National Cholesterol Education Program (NCEP) Adult Treatment Panel III guidelines.


Know the red flags of hereditary cancers

Crockett-Maillet, Ginny

The Nurse Practitioner. 35(7):39-43, July 2010.

The identification of susceptibility for hereditary cancer in asymptomatic individuals provides vital information about potential genetic risk and affords the opportunity for early intervention through genetic counseling and testing.


Lyme disease: A diagnostic dilemma

Savely, Virginia

The Nurse Practitioner. 35(7):44-50, July 2010.

Lyme disease is often missed in its early stages when treatment is most successful, and years of needless morbidity and disability ensue for thousands of patients. This article presents the diagnostic challenges inherent in the diagnosis of Lyme disease and provides information about when to suspect Lyme disease and how to test for it.


Osteonecrosis of the jaw & osteoporosis therapy

Kessenich, Cathy R.

The Nurse Practitioner. 35(7):51-53, July 2010.

According to a task force convened by the American Society of Bone and Mineral Research, the risk of osteonecrosis of the jaw (ONJ) associated with oral bisphosphonate therapy for osteoporosis is low and estimated at 1 in 10,000 and less than 1 in 100,000 patient-treatment years. Comparatively, the risk of ONJ in patients with cancer treated with high doses of intravenous bisphosphonates is higher and estimated at 1-10 per 100 patients treated.